Physician profile
Saria Refai
NPI 1750530754
$8,686.64
in general payments reported to CMS, 2019-2025
51 companies · $2,824 in 2025
The $2,824 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,760 · 2020: $437 · 2021: $482 · 2022: $924 · 2023: $1,150 · 2024: $1,111 · 2025: $2,824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,013 · Education: $71.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,012.88 |
| Education | $71.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,674.36 | 2021-2025 | |
| Ucb, INC. | $713.57 | 2019-2025 | Rystiggo, Briviact, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $626.61 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Argenx US, INC. | $468.20 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Allergan, INC. | $378.49 | 2019-2022 | |
| Lundbeck LLC | $367.77 | 2019-2025 | Vyepti, Rexulti |
| Pfizer INC. | $352.14 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $343.00 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $304.25 | 2022-2025 | Xeomin, Inbrija |
| Alexion Pharmaceuticals, INC. | $268.76 | 2019-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $261.66 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $245.15 | 2019-2024 | Rytary, Ongentys |
| Genentech USA, INC. | $221.99 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Acadia Pharmaceuticals INC | $217.77 | 2019-2024 | Nuplazid |
| Sk Life Science, INC. | $198.99 | 2022-2025 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $174.41 | 2024-2025 | |
| Biogen, INC. | $173.99 | 2019-2022 | |
| Lilly USA, LLC | $163.87 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Amgen INC. | $158.56 | 2019-2025 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $116.77 | 2022 | |
| Adamas Pharmaceuticals, INC. | $108.31 | 2019-2020 | |
| Eisai INC. | $97.07 | 2020-2025 | |
| Kyowa Kirin, INC. | $79.55 | 2023-2024 | Nourianz |
| Neurocrine Biosciences, INC. | $79.30 | 2022-2025 | Ongentys, Ingrezza |
| Astrazeneca Pharmaceuticals LP | $75.71 | 2024-2025 | Wainua |
| Abbott Laboratories | $73.62 | 2022-2023 | Infinity |
| Celgene Corporation | $73.33 | 2021-2025 | Zeposia |
| Sumitomo Pharma America, INC. | $60.59 | 2023-2024 | Aptiom |
| E.R. Squibb & Sons, L.L.C. | $58.89 | 2020-2021 | |
| Csl Behring | $58.69 | 2020-2025 | Hizentra |
| Avanir Pharmaceuticals, INC. | $43.86 | 2019-2020 | |
| Genzyme Corporation | $37.96 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $36.71 | 2022 | |
| Corium, LLC | $34.20 | 2022-2023 | Adlarity |
| Promius Pharma LLC | $33.33 | 2019 | |
| Ceribell, INC. | $32.50 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $32.36 | 2021 | |
| Livanova USA, INC. | $27.69 | 2021 | |
| Assertio Therapeutics, INC. | $27.31 | 2019 | |
| Silk Road Medical, INC. | $22.35 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Dynasplint Systems INC. | $20.27 | 2025 | Dynasplint |
| Mdd US Operations, LLC | $18.44 | 2024 | Apokyn |
| Avion Pharmaceuticals | $16.86 | 2022 | |
| Impel Pharmaceuticals INC. | $15.52 | 2023 | Trudhesa |
| Tonix Medicines, INC. | $14.22 | 2025 | Zembrace Symtouch |
| Tanabe Pharma America, INC. | $14.19 | 2019 | |
| Axsome Therapeutics, INC. | $14.05 | 2025 | Symbravo |
| Acorda Therapeutics, INC | $12.80 | 2019 | |
| Cala Health, INC. | $12.72 | 2023 | Cala Trio |
| Collegium Pharmaceutical, INC. | $12.17 | 2022 | |
| Almatica Pharma LLC | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saria Refai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.